AlzeCure Pharma AB (publ) (“AlzeCure” or the “Company”) has successfully completed a capital raise totaling approximately SEK 58 million before issue costs, consisting of a rights issue and a directed share issue under an overallotment option (the “Share Issues”). The capital raise was heavily oversubscribed and received strong interest from both existing shareholders and new investors.

Background and motive
AlzeCure is a Swedish biotech company that develops innovative small molecule drug candidates for diseases affecting the central nervous system, with a primary focus on Alzheimer’s disease and pain. The Company’s portfolio includes multiple preclinical and clinical-stage programs, with its lead asset ACD856 currently in clinical phase targeting cognitive disorders.

The purpose of the capital raise is to secure financing for continued development of the Company’s clinical and preclinical programs, strengthen its financial position ahead of potential partnership discussions, and support general working capital needs.

The rights issue raised approximately SEK 48.5 million and was heavily oversubscribed, indicating strong confidence in AlzeCure’s long-term strategy. In light of the high demand, the Company’s Board of Directors also resolved on a directed share issue under the framework of an overallotment option, adding a further SEK 10 million in gross proceeds.

About AlzeCure Pharma
AlzeCure Pharma is a clinical-stage biotech company headquartered in Stockholm, Sweden. The Company is focused on developing novel small molecule drug candidates for the treatment of central nervous system disorders, including Alzheimer’s disease and pain. Its research platform and pipeline are based on cutting-edge science, aimed at addressing major unmet medical needs with high commercial potential.

Corpura acted as Joint Bookrunner in connection with the capital raise.

For more information contact:
Jonatan Andersson
Phone: +46 (0)70-508 00 51
Email: jonatan.andersson@corpura.se

‍